ESMO22 EXPERT REPORT ON NEOADJUVANT IMMUNE CHECKPOINT INHIBITORS FOR MELANOMA
Source: Oncology Pro, September 2022
Olivier Michielin discusses abstracts presented at ESMO Congress 2022:
– LBA6: Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
– LBA39: Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)
This video was supported with an educational grant from Roche.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.